|
|
14 April 2021 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces the following PDMR share transactions.
As part of the Company’s Deferred Share Bonus Plan (DSB), Executive Directors and employees can sacrifice part of their annual bonus to be invested in the DSB, which for every share purchased on behalf of the employee they receive matching shares which are deferred for a minimum of three years. As a result of there being no Executive bonuses being awarded for the financial year ended 31 December 2020 due to the financial impact of COVID-19, Chris Meredith (CEO) and Eddie Johnson (CFO) have elected to sell certain existing shares to use the proceeds to re-invest in the DSB. The decision to participate in the DSB was taken on 7 April 2021.
The Company was notified on 9 April 2021 that following his decision to participate on 7 April, Chris Meredith, who is a Director and PDMR, executed the exercise of 23,369 options from the existing Deferred Annual Bonus Plan (DAB). Chris Meredith elected to receive an additional 272 dividend shares which were earned during the holding period under the terms of the DAB. Chris Meredith has also executed the exercise of 3,010 Ordinary Shares of 5p from the existing DSB and subsequently sold 28,156 Ordinary Shares of 5p each on 9 April 2021 at a share price of 241p per Ordinary Share. The proceeds from the sale of the shares will be used to purchase shares in the DSB which administratively occurs in May 2021, and will increase Chris Meredith’s beneficial interest in the Company from the level prior to these transactions.
As a result of these transactions Chris Meredith’s beneficial interest in the Company is as follows, prior to the purchase of shares in May 2021:
Deferred Share Bonus Plan (DSB)
|
PDMR |
No. of DSBs prior to exercise |
DSBs exercised |
Ordinary Shares sold |
Ordinary Shares retained |
DSBs after exercise |
|
Chris Meredith |
60,300 |
3,010 |
3,010 |
Nil |
57,290 |
Deferred Annual Bonus Plan (DAB)
|
PDMR |
DABs prior to exercise |
DABs exercised |
Dividend Shares received |
Ordinary Shares sold |
Ordinary Shares retained |
DABs after exercise |
|
Chris Meredith |
57,977 |
23,369 |
272 |
23,641 |
Nil |
34,608 |
Overall Holding
|
PDMR |
Holding prior to exercise |
Number of shares exercised |
Dividend Shares received |
Number of shares sold |
Sale price (p) |
Resultant holding |
% of issued share capital |
|
Chris Meredith |
1,511,550 |
26,379 |
272 |
28,156 |
241p |
1,510,045 |
0.7% |
The Company was notified on 9 April 2021 that following his decision to participate on 7 April, Eddie Johnson, who is a Director and PDMR, executed the exercise of 17,254 Ordinary Shares of 5p from the existing DSB and subsequently sold 19,193 Ordinary Shares of 5p each on 9 April 2021 at a share price of 241p per Ordinary Share. The proceeds from the sale of the shares will be entirely used to purchase shares in the DSB which administratively occurs in May 2021, and will increase Eddie Johnson’s beneficial interest in the Company from the level prior to these transactions.
As a result of these transactions Eddie Johnson’s beneficial interest in the Company is as follows, prior to the purchase of shares in May 2021:
Deferred Share Bonus Plan (DSB)
|
PDMR |
No. of DSBs prior to exercise |
DSBs exercised |
Ordinary Shares sold |
Ordinary Shares retained |
DSBs after exercise |
|
Eddie Johnson |
91,618 |
17,254 |
17,254 |
Nil |
74,364 |
Overall Holding
|
PDMR |
Holding prior to exercise |
Number of shares exercised |
Dividend Shares received |
Number of shares sold |
Sale price (p) |
Resultant holding |
% of issued share capital |
|
Eddie Johnson |
67,967 |
17,254 |
0 |
19,193 |
241p |
66,028 |
0.03% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Exercise of 23,369 shares from the Deferred Annual Bonus Plan · Award of 272 Dividend Shares from the Deferred Annual Bonus Plan · Exercise of 3,010 shares from the Deferred Share Bonus Plan · Sale of 28,156 Ordinary Shares of 5p |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 28,156 Aggregated price: £2.41 |
||||
|
e) |
Date of the transaction: 09/04/2021 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transaction: · Exercise of 17,254 shares from the Deferred Share Bonus Plan · Sale of 19,193 Ordinary Shares of 5p |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 19,193 Aggregated price: £2.41 |
||||
|
e) |
Date of the transaction: 09/04/2021 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: 44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: 44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Olivia Manser |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: 44 (0) 20 7597 5970 |
|
Daniel Adams / Gary Clarence / Patrick Robb |
|
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.
AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBRGDSIGBDGBS